The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double-blinded, placebo-controlled trial.
Pediatr Allergy Immunol
; 29(8): 834-840, 2018 12.
Article
em En
| MEDLINE
| ID: mdl-30160043
ABSTRACT
BACKGROUND:
The aim of this clinical trial was to determine the effects of melatonin administration on disease severity and sleep quality in children diagnosed with atopic dermatitis (AD).METHODS:
This randomized, double-blinded, placebo-controlled trial was conducted by recruiting 70 patients, aged 6-12 years, who had been diagnosed with AD. Study participants were randomly allocated into two intervention groups to receive either 6 mg/d melatonin supplements or placebo (n = 35 each group) for 6 weeks. Severity of disease was assessed using the scoring atopic dermatitis (SCORAD) and objective SCORAD indices. Sleep quality was evaluated by completing the Children's Sleep Habits Questionnaire (CSHQ).RESULTS:
Following 6 weeks of intervention, melatonin supplementation significantly improved SCORAD index (ß -3.55; 95% CI, -6.11, -0.98; P = 0.007), objective SCORAD index (ß -3.23; 95% CI, -5.08, -1.38; P = 0.001), serum total IgE levels (ß -153.94 ku/L; 95% CI, -260.39, -47.49; P = 0.005), and CSHQ scores (ß -2.55; 95% CI, -4.34, -0.75; P = 0.006). However, melatonin had no significant impact on pruritus scores, high-sensitivity C-reactive protein (hs-CRP), sleep-onset latency, total sleep time, weight, and BMI compared with placebo.CONCLUSIONS:
Overall, melatonin supplementation had beneficial effects on disease severity, serum total IgE levels, and CSHQ among children diagnosed with AD.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sono
/
Dermatite Atópica
/
Melatonina
Tipo de estudo:
Clinical_trials
Limite:
Child
/
Female
/
Humans
/
Male
País como assunto:
Asia
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article